Headlands Research announced the opening of Headlands Research Twin Cities (HRTC), its 23rd fully owned site. Strategically situated in the Minneapolis–St. Paul metro area, the new center offers pharmaceutical sponsors and CROs rapid, single-contract access to a wide range of Upper-Midwest patient populations.
"The Twin Cities are a major healthcare hub for the Upper Midwest," said Kyle Burtnett, CEO of Headlands Research. "Combining Principal Investigator Dr. Charlene McEvoy's extensive respiratory expertise with our network-wide technology, SOPs, and quality systems, we can help sponsors accelerate enrollment in sleep, pulmonology, metabolic, and general-medicine studies while maintaining the data integrity they expect."
HRTC will be led by Dr. McEvoy, a board-certified pulmonologist and sleep medicine specialist with over 25 years of experience in clinical research. Her established relationships with regional health systems and community organizations position the site to launch studies quickly, recruit and retain participants effectively, and meet trial endpoints with compliance. Sponsors will also benefit from Headlands Research's centralized contracting, validated data platforms, and 5,000-trial track record, eliminating the fragmentation often encountered when engaging independent sites.
"Patients in our region deserve earlier access to cutting-edge therapies," said Dr. McEvoy, Principal Investigator at HRTC. "Joining the Headlands network allows us to combine local trust and outreach with enterprise-grade operational support, bringing novel treatments to patients faster and more reliably."